BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 25456905)

  • 1. Dicer expression and microRNA dysregulation associate with aggressive features in thyroid cancer.
    Erler P; Keutgen XM; Crowley MJ; Zetoune T; Kundel A; Kleiman D; Beninato T; Scognamiglio T; Elemento O; Zarnegar R; Fahey TJ
    Surgery; 2014 Dec; 156(6):1342-50; discussion 1350. PubMed ID: 25456905
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New global analysis of the microRNA transcriptome of primary tumors and lymph node metastases of papillary thyroid cancer.
    Saiselet M; Gacquer D; Spinette A; Craciun L; Decaussin-Petrucci M; Andry G; Detours V; Maenhaut C
    BMC Genomics; 2015 Oct; 16():828. PubMed ID: 26487287
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intercellular adhesion molecule-1 (ICAM-1) is upregulated in aggressive papillary thyroid carcinoma.
    Buitrago D; Keutgen XM; Crowley M; Filicori F; Aldailami H; Hoda R; Liu YF; Hoda RS; Scognamiglio T; Jin M; Fahey TJ; Zarnegar R
    Ann Surg Oncol; 2012 Mar; 19(3):973-80. PubMed ID: 21879273
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dysregulated expression of Dicer in invasive ductal breast carcinoma.
    Poursadegh Zonouzi AA; Nejatizadeh A; Rahmati-Yamchi M; Fardmanesh H; Shakerizadeh S; Poursadegh Zonouzi A; Nejati-Koshki K; Shekari M
    Med Oncol; 2015 Jul; 32(7):203. PubMed ID: 26076803
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dicer is down-regulated in clear cell renal cell carcinoma and in vitro Dicer knockdown enhances malignant phenotype transformation.
    Ma X; Fan Y; Gao Y; Zhang Y; Huang Q; Ai Q; Ni D; Chen W; Zhang P; Song E; Wang B; Shi T; Zheng T; Zhang X
    Urol Oncol; 2014 Jan; 32(1):46.e9-17. PubMed ID: 24094887
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Expression of microRNA-221 and IL-17 in papillary thyroid carcinoma and correlation with clinicopathologic features].
    Jiang XL; Zhang H; Chen YL; Peng L
    Zhonghua Bing Li Xue Za Zhi; 2017 Mar; 46(3):160-165. PubMed ID: 28297755
    [No Abstract]   [Full Text] [Related]  

  • 7. Expressions of miRNAs in papillary thyroid carcinoma and their associations with the BRAFV600E mutation.
    Huang Y; Liao D; Pan L; Ye R; Li X; Wang S; Ye C; Chen L
    Eur J Endocrinol; 2013 May; 168(5):675-81. PubMed ID: 23416953
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MUC1 expression in papillary thyroid carcinoma is associated with BRAF mutation and lymph node metastasis; the latter is the most important risk factor of relapse.
    Renaud F; Gnemmi V; Devos P; Aubert S; Crépin M; Coppin L; Ramdane N; Bouchindhomme B; d'Herbomez M; Van Seuningen I; Do Cao C; Pattou F; Carnaille B; Pigny P; Wémeau JL; Leteurtre E
    Thyroid; 2014 Sep; 24(9):1375-84. PubMed ID: 25012490
    [TBL] [Abstract][Full Text] [Related]  

  • 9. E-selectin expression and BRAF status in papillary thyroid carcinomas: Correlation with clinicopathologic features.
    Miccoli P; Torregrossa L; Borrelli N; Materazzi G; Cacciato Insilla A; Miccoli M; Basolo F
    Surgery; 2014 Dec; 156(6):1550-7; discussion 1557-8. PubMed ID: 25456953
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The microRNA-processing enzymes: Drosha and Dicer can predict prognosis of nasopharyngeal carcinoma.
    Guo X; Liao Q; Chen P; Li X; Xiong W; Ma J; Li X; Luo Z; Tang H; Deng M; Zheng Y; Wang R; Zhang W; Li G
    J Cancer Res Clin Oncol; 2012 Jan; 138(1):49-56. PubMed ID: 21953080
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinicopathologic correlations of the BRAFV600E mutation, BRAF V600E immunohistochemistry, and BRAF RNA in situ hybridization in papillary thyroid carcinoma.
    Jung YY; Yoo JH; Park ES; Kim MK; Lee TJ; Cho BY; Chung YJ; Kang KH; Ahn HY; Kim HS
    Pathol Res Pract; 2015 Feb; 211(2):162-70. PubMed ID: 25468810
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Integrated analyses of microRNA and mRNA expression profiles in aggressive papillary thyroid carcinoma.
    Yang Z; Yuan Z; Fan Y; Deng X; Zheng Q
    Mol Med Rep; 2013 Nov; 8(5):1353-8. PubMed ID: 24064622
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overexpression of miR-221 is associated with aggressive clinicopathologic characteristics and the BRAF mutation in papillary thyroid carcinomas.
    Zhou YL; Liu C; Dai XX; Zhang XH; Wang OC
    Med Oncol; 2012 Dec; 29(5):3360-6. PubMed ID: 22855362
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of the microRNA regulators Drosha, Dicer and Ago2 in non-small cell lung carcinomas.
    Prodromaki E; Korpetinou A; Giannopoulou E; Vlotinou E; Chatziathanasiadou Μ; Papachristou NI; Scopa CD; Papadaki H; Kalofonos HP; Papachristou DJ
    Cell Oncol (Dordr); 2015 Aug; 38(4):307-17. PubMed ID: 26227789
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Up-regulation of urinary-type plasminogen activator correlates with high-risk papillary thyroid carcinoma with BRAF(V600E) mutation and its possible molecular mechanism.
    Wakasa T; Li Y; Bai Y; Liu Z; Ozaki T; Mori I; Miyauchi A; Kakudo K; Nakamura M
    Pathol Res Pract; 2014 Nov; 210(11):733-8. PubMed ID: 25085839
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of BRAF(V600E) mutation as poor prognostic factor for the outcome of patients with intrathyroid papillary thyroid carcinoma.
    Pelizzo MR; Dobrinja C; Casal Ide E; Zane M; Lora O; Toniato A; Mian C; Barollo S; Izuzquiza M; Guerrini J; De Manzini N; Merante Boschin I; Rubello D
    Biomed Pharmacother; 2014 May; 68(4):413-7. PubMed ID: 24721322
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RAC1b overexpression in papillary thyroid carcinoma: a role to unravel.
    Silva AL; Carmo F; Bugalho MJ
    Eur J Endocrinol; 2013 Jun; 168(6):795-804. PubMed ID: 23482591
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Down-regulation of 14q32-encoded miRNAs and tumor suppressor role for miR-654-3p in papillary thyroid cancer.
    Geraldo MV; Nakaya HI; Kimura ET
    Oncotarget; 2017 Feb; 8(6):9597-9607. PubMed ID: 28030816
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Caveolin-1 expression in papillary thyroid carcinoma: correlation with clinicopathological parameters and BRAF mutation status.
    Paskaš S; Janković J; Marečko I; Išić Denčić T; Tatić S; Cvejić D; Savin S
    Otolaryngol Head Neck Surg; 2014 Feb; 150(2):201-9. PubMed ID: 24255086
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Value of immunohistochemistry in the detection of BRAF(V600E) mutations in fine-needle aspiration biopsies of papillary thyroid carcinoma.
    Zimmermann AK; Camenisch U; Rechsteiner MP; Bode-Lesniewska B; Rössle M
    Cancer Cytopathol; 2014 Jan; 122(1):48-58. PubMed ID: 24039206
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.